Associated Papers
Common epidermal growth factor receptor mutations in north Indian patients with non-small cell lung carcinoma: evidence from real-time polymerase chain reaction.
Behera R et al.
Monaldi Archives for Chest Disease = Archivio Monaldi Per Le Malattie Del Torace, 2025
Concurrent EGFR L858R and K860I mutations: PCR-negative but NGS-positive alterations that respond to EGFR inhibitors in non-small cell lung cancer.
Shi H et al.
Journal of Thoracic Disease, 2025
Predicting Resistance to Small Molecule Kinase Inhibitors.
Nagarajan A et al.
Journal of Chemical Information and Modeling, 2025
A macrocyclic kinase inhibitor overcomes triple resistant mutations in EGFR-positive lung cancer.
Suzuki M et al.
Npj Precision Oncology, 2024
Structure-Guided Strategies of Targeted Therapies for Patients with EGFR-Mutant Non-Small Cell Lung Cancer.
Du Z et al.
Biomolecules, 2023
L718Q/V mutation in exon 18 of EGFR mediates resistance to osimertinib: clinical features and treatment.
Li M et al.
Discover Oncology, 2022
Molecular Targets in Lung Cancer: Study of the Evolution of Biomarkers Associated with Treatment with Tyrosine Kinase Inhibitors-Has NF1 Tumor Suppressor a Key Role in Acquired Resistance?
Alen BO et al.
Cancers, 2022
Pedigree analysis of the EGFR p.V1010M germline mutation in a family with a family history of non-small-cell lung cancer.
Li N et al.
Annals of Translational Medicine, 2022
Osimertinib-Centered Therapy Against Uncommon Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer- A Mini Review.
Song C et al.
Frontiers in Oncology, 2022
ALK-R3HDM1 and EML4-ALK fusion as a mechanism of acquired resistance to gefitinib: A case report and literature review.
Zeng Z et al.
Frontiers in Oncology, 2022
NSCLC patients with rare EGFR Ex19del/G724S mutation showed good response to afatinib combined with chemotherapy treatment: A two-case report.
Wang H et al.
Frontiers in Oncology, 2022
Primary Erlotinib Resistance in a Patient with Non-Small Cell Lung Cancer Carrying Simultaneous Compound EGFR L718A, Q849H, and L858R Mutations.
Mirtavoos-Mahyari H et al.
Biomolecular Concepts, 2021
FBXL2 counteracts Grp94 to destabilize EGFR and inhibit EGFR-driven NSCLC growth.
Niu M et al.
Nature Communications, 2021
Driver gene alterations profiling of Chinese non-small cell lung cancer and the effects of co-occurring alterations on immunotherapy.
Sun S et al.
Cancer Medicine, 2021
Molecular pathogenesis of hereditary lung cancer: a literature review.
Rammal S et al.
Pharmacogenomics, 2021
Profiling Oncogenic Germline Mutations in Unselected Chinese Lung Cancer Patients.
Yang J et al.
Frontiers in Oncology, 2021
EGFR-Mutated Squamous Cell Lung Cancer and Its Association With Outcomes.
Jin R et al.
Frontiers in Oncology, 2021
A Highly Sensitive Next-Generation Sequencing-Based Genotyping Platform for EGFR Mutations in Plasma from Non-Small Cell Lung Cancer Patients.
Shin JY et al.
Cancers, 2020
Emerging EML4-ALK Variant 5 as a Concurrent Resistance Mechanism to Osimertinib in a Patient With EGFR E19del/T790M NSCLC.
Yan Y et al.
Clinical Lung Cancer, 2020
Genetic alterations in epidermal growth factor receptor-tyrosine kinase inhibitor-naïve non-small cell lung carcinoma.
Yamaura T et al.
Oncology Letters, 2020
The contribution of hereditary cancer-related germline mutations to lung cancer susceptibility.
Liu M et al.
Translational Lung Cancer Research, 2020
Interaction and molecular dynamics simulation study of Osimertinib (AstraZeneca 9291) anticancer drug with the EGFR kinase domain in native protein and mutated L844V and C797S.
Assadollahi V et al.
Journal of Cellular Biochemistry, 2019
EGFR and ERBB2 Germline Mutations in Chinese Lung Cancer Patients and Their Roles in Genetic Susceptibility to Cancer.
Lu S et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 2019
Characterization of acquired receptor tyrosine-kinase fusions as mechanisms of resistance to EGFR tyrosine-kinase inhibitors.
Xu H et al.
Cancer Management and Research, 2019
Application of dynamic monitoring of genomic profiles in non-small cell lung cancer: A case report.
Kuang BH et al.
Medicine, 2018
Targeting EGFRL858R/T790M and EGFRL858R/T790M/C797S resistance mutations in NSCLC: Current developments in medicinal chemistry.
Lu X et al.
Medicinal Research Reviews, 2018
Crystal structure of EGFR T790M/C797S/V948R in complex with EAI045.
Zhao P et al.
Biochemical and Biophysical Research Communications, 2018
Evolution of oncogenic signatures of mutation hotspots in tyrosine kinases supports the atavistic hypothesis of cancer.
Chen W et al.
Scientific Reports, 2018
Structural insights into drug development strategy targeting EGFR T790M/C797S.
Zhu SJ et al.
Oncotarget, 2018
Structural basis of mutant-selectivity and drug-resistance related to CO-1686.
Yan XE et al.
Oncotarget, 2017
Treatment in EGFR-mutated non-small cell lung cancer: how to block the receptor and overcome resistance mechanisms.
Proto C et al.
Tumori, 2017
Recent Development of the Second and Third Generation Irreversible Epidermal Growth Factor Receptor Inhibitors.
Han W et al.
Chemistry & Biodiversity, 2017
Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy.
Santarpia M et al.
Lung Cancer (auckland, N.z.), 2017
Cis-oriented solvent-front EGFR G796S mutation in tissue and ctDNA in a patient progressing on osimertinib: a case report and review of the literature.
Klempner SJ et al.
Lung Cancer (auckland, N.z.), 2017
Challenges and Perspectives on the Development of Small-Molecule EGFR Inhibitors against T790M-Mediated Resistance in Non-Small-Cell Lung Cancer.
Song Z et al.
Journal of Medicinal Chemistry, 2016
EGFR C797S mutation mediates resistance to third-generation inhibitors in T790M-positive non-small cell lung cancer.
Wang S et al.
Journal of Hematology & Oncology, 2016
Acquired C797S Mutation upon Treatment with a T790M-Specific Third-Generation EGFR Inhibitor (HM61713) in Non-Small Cell Lung Cancer.
Song HN et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 2016
Third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer.
Pirker R
Current Opinion in Oncology, 2016
Development of epidermal growth factor receptor tyrosine kinase inhibitors against EGFR T790M. Mutation in non small-cell lung carcinoma.
Wang Y et al.
Open Medicine (warsaw, Poland), 2016
EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors.
Ercan D et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2015
Emerging Agents and New Mutations in EGFR-Mutant Lung Cancer.
Ayeni D et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2015
Gefitinib.
Rawluk J et al.
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer, 0